Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
What is Chongqing Genrix Biopharmaceutical Co Current Ratio?
Chongqing Genrix Biopharmaceutical CoSHSE:688443 +0.81%43 Current Ratio is 4.78 as of Mar. 2026, which is 30% below its 10-year median of 6.87. GuruFocus rates SHSE:688443 with a GF Score™ of 43/100. The stock has 4 warning signs investors should review. Among 1,411 Biotechnology companies, Chongqing Genrix Biopharmaceutical Co ranks better than 56.2% on this metric.
Chongqing Genrix Biopharmaceutical Co has a current ratio of 4.78. It indicates the company may not be efficiently using its current assets or its short-term financing facilities. This may also indicate problems in working capital management.
SHSE:688443's Current Ratio is ranked better than 56.2% of 1411
companies
in the Biotechnology industry
Industry Median: 3.88
vs SHSE:688443: 4.78
Chongqing Genrix Biopharmaceutical Co (SHSE:688443) Current Ratio Explanation
The current ratio can give a sense of the efficiency of a company's operating cycle or its ability to turn its product into cash. Companies that have trouble getting paid on their receivables or have long inventory turnover can run into liquidity problems because they are unable to alleviate their obligations. Because business operations differ in each industry, it is always more useful to compare companies within the same industry.
Acceptable current ratios vary from industry to industry and are generally between 1 and 3 for healthy businesses.
The higher the current ratio, the more capable the company is of paying its obligations. A ratio under 1 suggests that the company would be unable to pay off its obligations if they came due at that point. While this shows the company is not in good financial health, it does not necessarily mean that it will go bankrupt - as there are many ways to access financing - but it is definitely not a good sign.
If all other things were equal, a creditor, who is expecting to be paid in the next 12 months, would consider a high current ratio to be better than a low current ratio, because a high current ratio means that the company is more likely to meet its liabilities which fall due in the next 12 months.
Chongqing Genrix Biopharmaceutical Co Current Ratio Related Terms
Chongqing Genrix Biopharmaceutical Co Current Ratio Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Chongqing Genrix Biopharmaceutical Co Current Ratio Chart
SHSE:688443 vs VRTX, REGN, ALNY: Current Ratio Comparison
For the Biotechnology subindustry, Chongqing Genrix Biopharmaceutical Co's Current Ratio, along with its competitors' market caps and Current Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Chongqing Genrix Biopharmaceutical Co Current Ratio vs Biotechnology Industry
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Chongqing Genrix Biopharmaceutical Co (SHSE:688443) has a Current Ratio of 4.78 as of Mar. 2026. This is 30% below median its historical median of 6.87. Over the past decade, Chongqing Genrix Biopharmaceutical Co's Current Ratio has ranged from 0.17 to 28.57. According to the industry distribution chart, Chongqing Genrix Biopharmaceutical Co ranks #618 out of 1411 companies in the Biotechnology industry, placing it in the top 43.8%.
Is Chongqing Genrix Biopharmaceutical Co's Current Ratio too high?
Chongqing Genrix Biopharmaceutical Co's current Current Ratio of 4.78 is 30% below median its 10-year median of 6.87. Over the past 10 years, this metric has ranged from a low of 0.17 to a high of 28.57. The Biotechnology industry median Current Ratio is 3.88. Chongqing Genrix Biopharmaceutical Co's value of 4.78 is 23.2% above this industry median. Based on the distribution chart, Chongqing Genrix Biopharmaceutical Co ranks #618 out of 1411 companies in the Biotechnology industry, which is above the industry midpoint. Overall, Chongqing Genrix Biopharmaceutical Co has a GF Score™ of 43/100, reflecting its overall financial health beyond just this single metric.
How does Chongqing Genrix Biopharmaceutical Co's Current Ratio compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Chongqing Genrix Biopharmaceutical Co ranks #618 out of 1411 companies for Current Ratio. This puts Chongqing Genrix Biopharmaceutical Co in the upper half of its industry. The industry median Current Ratio is 3.88. Chongqing Genrix Biopharmaceutical Co's value of 4.78 is 23.2% above this benchmark. Historically, Chongqing Genrix Biopharmaceutical Co's own Current Ratio has ranged from 0.17 to 28.57 over the past decade. While the company's 10-year median is 6.87 vs. the industry median of 3.88, Chongqing Genrix Biopharmaceutical Co has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Current Ratio for a Biotechnology company?
The median Current Ratio among Biotechnology companies is 3.88, based on 1,411 companies in the industry. Companies in the top quartile (top 25%) have a Current Ratio significantly above this median, while those in the bottom quartile fall well below. However, Current Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Chongqing Genrix Biopharmaceutical Co's current Current Ratio of 4.78 is 23.2% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Current Ratio mean?
A high Current Ratio can signal that a stock is expensive relative to its fundamentals. For the Biotechnology industry, the median Current Ratio is 3.88 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Chongqing Genrix Biopharmaceutical Co's current Current Ratio is 4.78, which is 30% below median its own 10-year median of 6.87. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Chongqing Genrix Biopharmaceutical Co stock overvalued right now?
Chongqing Genrix Biopharmaceutical Co (SHSE:688443) has a current Current Ratio of 4.78. The current Current Ratio is 4.78, which is 30% below median its 10-year median of 6.87 and 23.2% above the Biotechnology industry median of 3.88. Chongqing Genrix Biopharmaceutical Co's overall GF Score™ is 43/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Current Ratio calculated?
Current Ratio is calculated from a company's financial statements. For Chongqing Genrix Biopharmaceutical Co (SHSE:688443), the current Current Ratio is 4.78 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Chongqing Genrix Biopharmaceutical Co Business Description
Chongqing Genrix Biopharmaceutical Co Ltd is a biopharmaceutical company engaged in the research & development, production and sales of antibody drugs. The company's pipeline includes product candidate that targets Autoimmune Diseases, Infectious Diseases, and Oncology.
43GF Score
Get the complete analysis for SHSE:688443
Current Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
SHSE:688443 has been successfully added to your 
